Can I Take Vitamin B12 with Addyi (Flibanserin)?

Why This Question Comes Up

Many women prescribed flibanserin already take daily supplements, and vitamin B12 is among the most common. Roughly 86% of U.S. Adults report using at least one dietary supplement, according to the Council for Responsible Nutrition's 2023 consumer survey. Because Addyi carries a boxed warning related to hypotension and syncope with certain interacting substances, patients reasonably worry about layering any pill on top of it.

Where the Concern Originates

The worry is partly inherited from metformin co-prescribing. A subset of women with HSDD also manage insulin resistance or polycystic ovary syndrome (PCOS) with metformin. Metformin reduces serum B12 by impairing ileal absorption through calcium-dependent membrane disruption [1]. When flibanserin enters the picture, patients and clinicians want to confirm that adding B12 supplementation won't alter flibanserin's CNS activity or clearance.

The Short Answer

No pharmacokinetic or pharmacodynamic conflict exists between these two compounds. They occupy entirely different metabolic pathways and receptor systems.

How Flibanserin Works in the Body

Flibanserin is a postsynaptic 5-HT1A agonist and 5-HT2A antagonist that modulates serotonin, dopamine, and norepinephrine activity in the prefrontal cortex [2]. The FDA approved it in August 2015 after three phase III trials. It does not act on peripheral vasculature, coagulation factors, or vitamin transport systems.

CYP3A4-Driven Metabolism

After oral dosing at 100 mg nightly, flibanserin reaches peak plasma concentration in about 0.75 hours. It undergoes extensive first-pass hepatic metabolism, primarily via CYP3A4 with minor contributions from CYP2C19 and CYP2D6 [3]. The elimination half-life is approximately 11 hours. Strong CYP3A4 inhibitors (ketoconazole, fluconazole, certain macrolide antibiotics) increase flibanserin exposure by up to 4.5-fold, which is why the FDA prescribing information contraindicates their concurrent use.

Why CYP Enzymes Matter Here

Vitamin B12, whether as cyanocobalamin or methylcobalamin, does not inhibit, induce, or serve as a substrate for any CYP450 isoenzyme. This is the single most important pharmacokinetic fact in this article. Because there is no shared enzyme pathway, B12 cannot raise or lower flibanserin plasma levels.

Vitamin B12 Pharmacology: A Separate Track

Vitamin B12 (cobalamin) is a water-soluble cofactor for methionine synthase and methylmalonyl-CoA mutase. It is absorbed in the terminal ileum via intrinsic factor binding, transported by transcobalamin II, and stored primarily in the liver (roughly 1 to 5 mg total body stores) [4].

Absorption and Elimination

Oral B12 supplements are absorbed through two pathways: intrinsic factor-mediated active transport (which saturates at roughly 1.5 mcg per meal) and passive diffusion across the intestinal mucosa (about 1% of a high oral dose). Excess B12 is filtered renally. No hepatic CYP processing is involved at any step. The kidneys handle elimination, and there is no enterohepatic recirculation interaction with the CYP3A4 pathway that governs flibanserin clearance.

No Receptor Overlap

B12 does not bind serotonin receptors, dopamine receptors, or norepinephrine transporters. Flibanserin's therapeutic target is the 5-HT1A/5-HT2A receptor system. These two compounds act on completely different biological systems, which rules out a pharmacodynamic interaction.

Evaluating the Interaction Risk

The Natural Medicines Comprehensive Database, Lexicomp, and the Addyi prescribing label list no interaction between flibanserin and vitamin B12. To understand why, it helps to walk through the standard interaction-screening framework.

Pharmacokinetic Screen

A pharmacokinetic interaction requires shared absorption sites, transport proteins, metabolizing enzymes, or excretion pathways. Flibanserin is absorbed in the upper GI tract and metabolized hepatically by CYP3A4. B12 is absorbed in the terminal ileum via intrinsic factor and cleared renally. There is zero overlap.

Pharmacodynamic Screen

A pharmacodynamic interaction requires opposing or additive effects on the same receptor, signaling cascade, or physiologic endpoint (e.g., blood pressure, QTc interval). B12 has no known effect on serotonin tone, blood pressure regulation, or CNS sedation. Flibanserin's boxed warning centers on additive hypotension with alcohol and additive CNS depression with CYP3A4 inhibitors. B12 does not contribute to either risk.

Clinical Evidence

No published case reports, pharmacovigilance signals in the FDA Adverse Event Reporting System (FAERS), or clinical trial data identify an adverse interaction between flibanserin and B12 supplementation.

The Metformin-B12-Flibanserin Triangle

This is where clinical nuance enters. While B12 and flibanserin do not interact with each other, metformin interacts with B12 absorption, and some patients take all three.

How Metformin Depletes B12

A 2010 analysis of the Diabetes Prevention Program Outcomes Study (DPPOS) found that metformin use for a mean of 3.2 years was associated with a twofold increased risk of B12 deficiency (OR 1.99, 95% CI 1.31 to 3.03) [5]. The mechanism involves calcium-dependent disruption of the intrinsic factor-cubam receptor complex in the ileum. This is a dose-dependent and duration-dependent effect.

Who Is at Risk

Women prescribed flibanserin who also take metformin for PCOS, prediabetes, or off-label weight management should have baseline and annual serum B12 levels drawn. The American Diabetes Association's 2024 Standards of Care recommends periodic B12 monitoring in patients on long-term metformin, particularly those with anemia or peripheral neuropathy [6].

Practical Monitoring Protocol

For the metformin-plus-flibanserin patient considering B12 supplementation:

• Draw serum B12 at baseline. Normal range is typically 200 to 900 pg/mL.
• If B12 is <300 pg/mL, add methylmalonic acid (MMA) testing. Elevated MMA (above 0.4 mcmol/L) confirms functional deficiency even when serum B12 appears borderline.
• Supplement with 1,000 mcg oral cyanocobalamin or methylcobalamin daily. This dose exploits passive diffusion, bypassing the intrinsic factor pathway that metformin disrupts [7].
• Recheck B12 and MMA at 3 months, then annually.

Dosing and Timing Recommendations

Because no interaction exists, there is no pharmacologic reason to separate flibanserin and B12 doses. Practical considerations may still guide timing.

Flibanserin Timing Is Fixed

The prescribing label specifies flibanserin 100 mg at bedtime. Taking it during waking hours increases the risk of hypotension, syncope, and accidental injury from CNS depression. This bedtime requirement is non-negotiable.

B12 Is Flexible

B12 can be taken at any time of day, with or without food, though absorption of oral B12 is slightly higher when taken with a meal containing protein (the acidic gastric environment liberates B12 from food-bound protein). Taking B12 in the morning with breakfast is a reasonable default, which also separates it from the bedtime flibanserin dose by 12 or more hours. This separation is a convenience measure, not a safety requirement.

Dose Ranges

Most over-the-counter B12 supplements range from 500 to 5,000 mcg. Because B12 has no established upper tolerable intake level (the Institute of Medicine did not set one due to low toxicity risk), high-dose supplementation is unlikely to cause harm [8]. Patients with confirmed deficiency typically start at 1,000 to 2,000 mcg daily.

When B12 Deficiency Mimics or Masks Symptoms

Clinicians should be aware that B12 deficiency and HSDD can share overlapping symptoms, which may complicate clinical assessment.

Fatigue and Low Mood

B12 deficiency causes megaloblastic anemia, leading to fatigue, irritability, and depressed mood [9]. These symptoms can reduce sexual desire independently of any HSDD neurobiology. A woman with undiagnosed B12 deficiency may appear to have HSDD that is refractory to flibanserin, when the underlying driver is a correctable nutritional deficit.

Neurologic Symptoms

Subacute combined degeneration from severe B12 deficiency produces paresthesias, proprioceptive loss, and gait ataxia. Flibanserin can cause dizziness and somnolence as listed adverse effects (reported in 11.4% and 11.2% of patients, respectively, in the BEGONIA trial, N=1,087) [10]. If a patient on flibanserin develops new-onset neurologic complaints, the differential should include B12 deficiency, not just a flibanserin side effect.

Checking the Right Labs

A complete workup includes:

• Serum B12 (may be falsely normal in 10-26% of deficient patients)
• Methylmalonic acid (more sensitive and specific)
• Homocysteine (elevated in both B12 and folate deficiency)
• Complete blood count with MCV (macrocytosis precedes anemia)

Special Populations

Older Premenopausal Women

Women in their late 30s and 40s who are still premenopausal (and therefore eligible for flibanserin) have increasing rates of atrophic gastritis, which reduces intrinsic factor production and B12 absorption. The NIH Office of Dietary Supplements recommends that adults over 50 obtain most B12 from supplements or fortified foods rather than relying on dietary intake alone.

Vegetarian and Vegan Patients

Plant-based diets contain virtually no bioavailable B12. A systematic review published in the European Journal of Clinical Nutrition found B12 deficiency rates of 62% in pregnant vegetarians and up to 90% in vegans not using supplements [11]. These patients need B12 supplementation regardless of flibanserin use, and should not delay starting it out of interaction concerns.

Patients on Proton Pump Inhibitors

PPIs reduce gastric acid secretion, impairing the release of protein-bound B12 from food. A 2013 case-control study of 25,956 patients with B12 deficiency found that PPI use for 2 or more years was associated with a 65% increased risk of deficiency (OR 1.65, 95% CI 1.58 to 1.73) [12]. PPI use does not interact with flibanserin either, but it compounds the B12 depletion risk.

What to Tell Your Prescriber

Patients already taking both flibanserin and B12 do not need to stop either one. The conversation with a prescriber should focus on three points:

1. Confirm that no strong or moderate CYP3A4 inhibitor is also in the medication list. This is the real risk axis for flibanserin interactions.
2. If metformin is part of the regimen, request B12 and MMA levels.
3. Report any new-onset numbness, tingling, or unsteadiness so the prescriber can distinguish B12 neuropathy from flibanserin side effects.

The Endocrine Society's 2019 clinical practice guideline on PCOS reinforces the importance of metabolic screening in women with hormonal and sexual health concerns, which may include B12 status when metformin is prescribed [13].

Bottom Line

Vitamin B12 and flibanserin occupy different metabolic territories. B12 uses intrinsic factor for absorption and renal pathways for excretion. Flibanserin relies on hepatic CYP3A4. No shared enzymes, no shared receptors, no documented adverse events. Patients prescribed 100 mg flibanserin at bedtime can take B12 at any time of day at standard supplement doses (500 to 2,000 mcg) without dose adjustment or additional monitoring beyond what their baseline clinical picture requires.